B Geoerger

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. ncbi request reprint Metabolic activity and clinical features of primary ganglioneuromas
    B Geoerger
    Children s Hospital, University of Cologne, Germany
    Cancer 91:1905-13. 2001
  2. doi request reprint A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study
    Birgit Geoerger
    Institut Gustave Roussy, Universite Paris Sud XI, Villejuif, France
    Eur J Cancer 48:289-96. 2012
  3. pmc Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
    Birgit Geoerger
    Institut Gustave Roussy, Department of Paediatric and Adolescent Medicine, University Paris Sud, Villejuif, France
    Eur J Cancer 48:253-62. 2012
  4. pmc Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
    Birgit Geoerger
    Department of Pediatrics, UPRES EA 3535 Pharmacology and New Treatments with Cancer, Institut Gustave Roussy, 94805 Villejuif, France
    Neuro Oncol 13:109-18. 2011
  5. doi request reprint Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study
    Birgit Geoerger
    Institut Gustave Roussy, Universite Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 47:230-8. 2011
  6. ncbi request reprint Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma
    Birgit Geoerger
    Department of Pediatrics, Institut Gustave Roussy, 94805 Villejuif, France
    J Gene Med 7:584-94. 2005
  7. doi request reprint Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma
    Birgit Geoerger
    UPRES EA 3535, Pharmacology and New Treatments of Cancer, Universite Paris Sud XI, Institut Gustave Roussy, 94805 Villejuif, France
    Eur J Cancer 46:3251-62. 2010
  8. pmc Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies
    B Geoerger
    Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 93:529-37. 2005
  9. doi request reprint Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
    Birgit Geoerger
    Department of Paediatrics, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 45:2342-51. 2009
  10. doi request reprint Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies
    Birgit Geoerger
    Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:4394-400. 2008

Detail Information

Publications35

  1. ncbi request reprint Metabolic activity and clinical features of primary ganglioneuromas
    B Geoerger
    Children s Hospital, University of Cologne, Germany
    Cancer 91:1905-13. 2001
    ..It may evolve from differentiating neuroblastoma or may be diagnosed as primary ganglioneuroma. The rarity of this tumor and the lack of understanding of its biology often lead to inaccurate diagnosis and treatment...
  2. doi request reprint A phase I and pharmacokinetic study of plitidepsin in children with advanced solid tumours: an Innovative Therapies for Children with Cancer (ITCC) study
    Birgit Geoerger
    Institut Gustave Roussy, Universite Paris Sud XI, Villejuif, France
    Eur J Cancer 48:289-96. 2012
    ....
  3. pmc Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
    Birgit Geoerger
    Institut Gustave Roussy, Department of Paediatric and Adolescent Medicine, University Paris Sud, Villejuif, France
    Eur J Cancer 48:253-62. 2012
    ..A phase II study of temsirolimus was conducted in children and adolescents with high-grade glioma, neuroblastoma or rhabdomyosarcoma...
  4. pmc Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
    Birgit Geoerger
    Department of Pediatrics, UPRES EA 3535 Pharmacology and New Treatments with Cancer, Institut Gustave Roussy, 94805 Villejuif, France
    Neuro Oncol 13:109-18. 2011
    ..6 hours. Thus, erlotinib 125 mg/m² per day has an acceptable tolerability profile in pediatric patients with brain tumors and can be combined with radiotherapy...
  5. doi request reprint Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study
    Birgit Geoerger
    Institut Gustave Roussy, Universite Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 47:230-8. 2011
    ..To assess objective response rates after 4 cycles of gemcitabine in combination with oxaliplatin in children and adolescents with relapsed or refractory solid tumours...
  6. ncbi request reprint Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma
    Birgit Geoerger
    Department of Pediatrics, Institut Gustave Roussy, 94805 Villejuif, France
    J Gene Med 7:584-94. 2005
    ..Derivative AdDelta24-425S11 infects cells deficient in coxsackie/adenovirus receptor (CAR) via the epidermal growth factor receptor (EGFR). Derivative AdDelta24-p53 expresses the tumor suppressor protein p53 to promote oncolysis...
  7. doi request reprint Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma
    Birgit Geoerger
    UPRES EA 3535, Pharmacology and New Treatments of Cancer, Universite Paris Sud XI, Institut Gustave Roussy, 94805 Villejuif, France
    Eur J Cancer 46:3251-62. 2010
    ..1d (p = ns) for temozolomide alone. Our results demonstrate the potential of the anti-IGF-1R antibody alone and in combination with alkylating agents and support the therapeutic development of the AVE1642 for aggressive neuroblastoma...
  8. pmc Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies
    B Geoerger
    Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
    Br J Cancer 93:529-37. 2005
    ....
  9. doi request reprint Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium
    Birgit Geoerger
    Department of Paediatrics, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Eur J Cancer 45:2342-51. 2009
    ..To explore imatinib efficacy and pharmacokinetics in children and adolescents with refractory/relapsing solid tumours, expressing imatinib-sensitive receptor tyrosine kinases...
  10. doi request reprint Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies
    Birgit Geoerger
    Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 26:4394-400. 2008
    ..To explore feasibility, maximum-tolerated dose (MTD), and recommended dose (RD) for phase II studies of weekly oxaliplatin for the treatment of relapsed or refractory pediatric solid malignancies...
  11. doi request reprint EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts
    Birgit Geoerger
    Université Paris XI IFR54, UPRES EA 3535 Pharmacology and New Treatment in Cancers, Institut Gustave Roussy, Villejuif, France
    Int J Cancer 123:209-16. 2008
    ..Thus, EGFR targeting through tyrosine kinase inhibition appears to be a promising new approach in the treatment of EGFR-driven glioma, particularly in combination with radiation therapy...
  12. ncbi request reprint [Targeted therapies in pediatric oncology: a new therapeutic approach?]
    C Jubert
    UPRES EA 3535, Departement de Pediatrie, Pharmacologie et Nouveaux Traitements des Cancers, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Arch Pediatr 13:189-94. 2006
    ..This new therapeutic approach necessitates well designed clinical trials that include relevant biomarkers to evaluate its real therapeutic potential...
  13. ncbi request reprint Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan
    L Calvet
    Pharmacology and New Treatments of Cancer UPRES EA, 3535 Institut Gustave Roussy, Villejuif, France
    Oncogene 25:3150-9. 2006
    ..Indeed, vasculature was significantly enhanced in resistant NB xenografts compared to sensitive and reverted xenografts, and we suggest that PTN is acting in our resistant in vivo NB model as an angiostatic factor...
  14. pmc Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts
    B Geoerger
    Department of Pediatrics, Institut Gustave Roussy, 94805 Villejuif, France
    Br J Cancer 89:577-84. 2003
    ..Interestingly, the oncolytic adenovirus seemed to accelerate radiation-induced tumour fibrosis. Potentiating antitumour activity suggests the development of this combined treatment for these highly malignant tumours...
  15. ncbi request reprint Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts
    Birgit Geoerger
    Department of Pediatrics, Laboratory of Pharmacotoxicology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94 805 Villejuif, France
    Cancer Res 62:764-72. 2002
    ..In conclusion, ONYX-015 displayed a major antitumor activity in human xenografts derived from primary malignant glioma supporting its development in the treatment of these highly malignant tumors...
  16. ncbi request reprint Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma
    Birgit Geoerger
    Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
    Cancer Res 64:5753-9. 2004
    ..We conclude that conditionally replicative adenoviruses expressing p53 are promising new agents for treatment of malignant glioma...
  17. doi request reprint [Potential role of antiangiogenic treatment in neuroblastoma]
    M Taylor
    Institut Gustave Roussy, UPRES EA3535 Pharmacologie et nouveaux traitements dans le cancer, Universite Paris Sud, 63, rue Gabriel Péri, 94276 Le Kremlin Bicetre, France
    Arch Pediatr 16:457-67. 2009
    ..Our review clearly demonstrates that clinical trials are urgently needed to bring forward promising antiangiogenesis concepts in neuroblastoma therapy...
  18. ncbi request reprint Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group
    Gilles Vassal
    Department of Pediatrics, Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 25:356-61. 2007
    ..This phase II study was designed to evaluate the efficacy of irinotecan administered intravenously once every 3 weeks in pediatric patients with recurrent or refractory rhabdomyosarcoma...
  19. ncbi request reprint [Conditionally replicative adenoviruses: a second wind for cancer gene therapy]
    Jacques Grill
    UPRES EA 3535, Pharmacologie et Nouveaux Traitements des Cancers, Institut Gustave Roussy, 94805 Villejuif
    Bull Cancer 90:1039-48. 2003
    ..First results are promising but complementary studies are needed to define if these agents will take place in the therapeutic armentorium against cancer...
  20. doi request reprint A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
    Gilles Vassal
    Department of Paediatrics, Institute Gustave Roussy, Villejuif, France
    Eur J Cancer 44:2453-60. 2008
    ..To evaluate the efficacy and safety of irinotecan in paediatric recurrent or refractory neuroblastoma...
  21. ncbi request reprint Pharmacokinetic and biological study of erlotinib in children as monotherapy for refractory brain tumors or with radiation for newly diagnosed brain stem gliomas
    B Geoerger
    Institut Gustave Roussy, Villejuif, France Royal Marsden Hospital, Sutton, United Kingdom Institut Claudius Regaud, Toulouse, France Sainte Anne Hospital, University of Paris, Paris, France Institut d Hématologie Oncologie Pédiatrique, Lyon, France Institut Curie, Paris, France Catholic University of Rome, Rome, Italy University Hospital Nottingham, Nottingham, United Kingdom
    J Clin Oncol 27:10019. 2009
    ..10019 Background: This multicenter phase I study was designed to determine the recommended dose (RD) of erlotinib, a small-molecule EGFR TKI, in patients ≤ 21 years as monotherapy or in combination with radiation therapy (RT)...
  22. ncbi request reprint p53 Pathway dysfunction in primary childhood ependymomas
    Nathalie Gaspar
    Pharmacology and New Treatments in Cancer UPRES EA 3535, Institut Gustave Roussy, Villejuif, France
    Pediatr Blood Cancer 46:604-13. 2006
    ..Childhood ependymoma remains a major therapeutic challenge despite surgery, chemotherapy, and irradiation. We hypothesized that p53 function might be abrogated in ependymomas and implicated in their resistance to anti-cancer therapy...
  23. ncbi request reprint Cell cycle and apoptotic effects of PM00104 in pediatric cell lines and xenographs
    A Beaugrand
    Institute Gustave Roussy, Villejuif, France University Children s Hospital, Muenster, Germany PharmaMar, Colmenar Viejo, Spain Institut Gustave Roussy, Villejuif, France Emma Children s Hospital Academic Medical Center, Amsterdam, Netherlands
    J Clin Oncol 29:9546. 2011
    ..9546 Background: PM00104 (Zalypsis) is a new synthetic alkaloid related to jorumycin and the renieramycins with in vitro growth-inhibitory properties in the low nanomolar range and anti-tumor activity in vivo against several adult cancers...
  24. ncbi request reprint Phase I-II clinical and pharmacokinetic study of plitidepsin in children with malignant tumors. On behalf of the European ITCC (Innovative Therapies for Children with Cancer) Consortium
    B Geoerger
    Institut Gustave Roussy, Villejuif, France Institut Curie, Paris, France Institute of Child Health, Birmingham, United Kingdom Royal Manchester Children s Hospital, Manchester, United Kingdom Royal Hospital for Sick Children, Glasgow, United Kingdom Centre Hopitalier Universitaire Nantes, Nantes, France PharmaMar SAU, Colmenar Viejo, Spain
    J Clin Oncol 26:10028. 2008
    ..Muscle and liver toxicities were dose-limiting toxicities (DLTs); hematological DLT was not observed at the recommended dose (RD)...
  25. ncbi request reprint Ethical issues in pediatric oncology phase I-II trials based on a mother's point of view
    D Oppenheim
    Pediatrics Department, and Unit of Psycho oncology, Institut Gustave Roussy, 94805 Villejuif Cedex, France
    Bull Cancer 92:E57-60. 2005
    ....
  26. ncbi request reprint Population pharmacokinetics of imatinib in children and adults
    E Chatelut
    Institut Claudius Regaud, Toulouse, France Institut Gustave Roussy, Villejuif, France Hôpital Henri Mondor, Creteil, France
    J Clin Oncol 26:2526. 2008
    ..2526 Background: The aim of this study was to explore the impact of several demographic, biological and pharmacogenetic covariates on imatinib and its main metabolite ( CGP74588 ) disposition...
  27. ncbi request reprint Phase I study of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed malignant tumors
    H Rubie
    CHU Toulouse, Toulouse, France Centre Leon Berard, Lyon, France Centre Oscar Lambret, Lille, France Institut Gustave Roussy, Villejuif, France Institut Curie, Paris, France CHU la Timone, Marseille, France Schering Plough, Levallois, France GlaxoSmithKline, Marly le Roi, France
    J Clin Oncol 26:13553. 2008
    ..The combination of TPT with TMZ has never been given in patients and our objective was to determine the recommended dose (RD) in children...
  28. ncbi request reprint NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric glial tumors
    G Berghtold
    Institute Gustave Roussy, Villejuif, France Hoffmann La Roche, Nutley, NJ American Memorial Hospital, Reims, France Institut Gustave Roussy, Villejuif, France Pediatric and Adolescent Oncology, Gustave Roussy Institute, Universite Paris Sud, Villejuif, France
    J Clin Oncol 29:9555. 2011
    ..9555 Background: Notch pathway signaling is deregulated in many human cancers, notably leukemia. Our recent findings in primary ependymoma suggest the NOTCH1 pathway is also implicated in glial oncogenesis (Puget et al. J Clin Oncol 2009)...
  29. doi request reprint High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies
    Melissa Taylor
    Laboratory of Translational Research, University of Paris Sud, UPRES EA 3535, Pharmacology and New Treatments in Cancer, France
    Clin Cancer Res 15:4561-71. 2009
    ..We measured these cells in patients with pediatric solid malignancies as a prerequisite to clinical trials with antiangiogenic therapy...
  30. doi request reprint Angiogenesis as a target in neuroblastoma
    Jochen Rossler
    Pharmacology and New Treatments in Cancer, Institut Gustave Roussy, University of Paris Sud, UPRES EA3535, Villejuif, France
    Eur J Cancer 44:1645-56. 2008
    ..This review clearly shows that angiogenesis is a target in NB and that clinical trials are urgently needed to bring forward promising anti-angiogenesis treatment strategies into NB therapy...
  31. ncbi request reprint Do medulloblastoma tumors meet the Food and Drug Administration criteria for anti-erbB2 therapy with trastuzumab?
    Natacha Entz-Werle
    INSERM U682, 3 avenue Moliere, 67200 Strasbourg, France
    Pediatr Blood Cancer 50:163-6. 2008
    ..Using the tools validated for breast cancers by the FDA, we did not observe any expression or amplification of erbB2 and hence we speculate that MBs are not a good target for treatment with anti-erbB2 antibodies...
  32. ncbi request reprint Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy
    Martine L M Lamfers
    Department of Neurosurgery, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Cancer Res 62:5736-42. 2002
    ..These results support further development of Ad5-Delta24RGD in combination with radiation therapy for treatment of these highly malignant tumors...
  33. ncbi request reprint Small molecule tyrosine kinase inhibitors: potential role in pediatric malignant solid tumors
    Jochen Rossler
    Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Hospital of Freiburg, 79106 Freiburg, Germany
    Curr Cancer Drug Targets 8:76-85. 2008
    ..In this review, we will address the data available supporting the potential use of tyrosine kinase inhibitors in solid malignancies of childhood...
  34. ncbi request reprint Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding
    Sydney M Evans
    School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 64:1886-92. 2004
    ..The proportion of moderately to severely hypoxic cells is relatively low, even in the high-grade tumors. Human brain tumors are dominated by oxic to moderately hypoxic cells...
  35. ncbi request reprint Stereotactic biopsy of diffuse pontine lesions in children
    Thomas Roujeau
    Department of Pediatric Neurosurgery, Hopital Necker Enfants Malades, Paris, France
    J Neurosurg 107:1-4. 2007
    ..To be included into a trial, patients need a definitive histological diagnosis. The authors present their prospective study of the stereotactic biopsy of these lesions during a 4-year period...